Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Constellation Pharmaceuticals	Kiniksa Pharmaceuticals	Omeros	Zogenix	Pliant Therapeutics
Symbol	NASDAQ:CNST	NASDAQ:KNSA	NASDAQ:OMER	NASDAQ:ZGNX	NASDAQ:PLRX
Price Information
Current Price	$20.80	$14.63	$17.75	$18.87	$32.90
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.2	1.7	1.4	1.7	2.0
Analysis Score	3.4	3.5	3.3	3.4	3.5
Community Score	2.4	2.4	3.0	2.8	4.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	2.5	0.8	1.7	1.7
Earnings & Valuation Score	0.0	0.0	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$40.33	$37.00	$23.00	$59.00	$49.20
% Upside from Price Target	93.91% upside	152.90% upside	29.58% upside	212.67% upside	49.54% upside
Trade Information
Market Cap	$996.61 million	$998.23 million	$1.11 billion	$1.05 billion	$1.18 billion
Beta	2.8	0.03	1.65	1.6	N/A
Average Volume	462,367	478,515	697,663	797,062	156,618
Sales & Book Value
Annual Revenue	N/A	N/A	$111.81 million	$3.65 million	$57.05 million
Price / Sales	N/A	N/A	9.89	288.55	20.69
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$8.23 per share	$4.10 per share	($2.19) per share	$5.54 per share	N/A
Price / Book	N/A	N/A	-8.11	3.41	∞
Profitability
Net Income	$-85,550,000.00	$-161,870,000.00	$-84,490,000.00	$-419,500,000.00	$-630,000.00
EPS	($3.04)	($2.99)	($0.96)	($3.90)	N/A
Trailing P/E Ratio	N/A	N/A	N/A	N/A	0.00
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-134.59%	-8,758.48%	20.83%
Return on Equity (ROE)	-28.88%	-53.65%	N/A	-53.91%	16.55%
Return on Assets (ROA)	-24.98%	-49.11%	-59.49%	-36.49%	8.33%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.05%	N/A	N/A	N/A	N/A
Current Ratio	15.81%	15.20%	4.11%	4.58%	27.91%
Quick Ratio	15.81%	15.20%	4.07%	4.58%	27.91%
Ownership Information
Institutional Ownership Percentage	N/A	42.00%	56.63%	96.57%	79.46%
Insider Ownership Percentage	10.60%	70.63%	11.30%	3.50%	N/A
Miscellaneous
Employees	154	168	277	218	78
Shares Outstanding	47.91 million	68.23 million	62.33 million	55.81 million	35.88 million
Next Earnings Date	5/10/2021 (Confirmed)	7/29/2021 (Estimated)	5/10/2021 (Confirmed)	8/4/2021 (Estimated)	6/15/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	Pliant Therapeutics (NASDAQ:PLRX) Sees Unusually-High Trading Volume americanbankingnews.com - May 7 at 11:54 AM
	Analyzing Pliant Therapeutics (NASDAQ:PLRX) and Astellas Pharma (OTCMKTS:ALPMY) americanbankingnews.com - May 6 at 1:48 PM
	Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference finance.yahoo.com - May 5 at 12:13 PM
	Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $33.50 americanbankingnews.com - May 3 at 12:04 PM
	We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth nasdaq.com - May 1 at 2:29 PM
	Pliant Therapeutics Inc (PLRX) investing.com - April 30 at 1:54 PM
	Pliant Therapeutics (NASDAQ:PLRX) Trading Down 5.2% americanbankingnews.com - April 28 at 12:38 PM
	Pliant Therapeutics (NASDAQ:PLRX) Earns Buy Rating from Analysts at BTIG Research americanbankingnews.com - April 26 at 11:00 AM
	Pliant Therapeutics (NASDAQ:PLRX) Now Covered by BTIG Research marketbeat.com - April 26 at 8:59 AM
	Pliant Therapeutics (NASDAQ:PLRX) PT Raised to $63.00 americanbankingnews.com - April 22 at 11:08 AM
	Pliant Therapeutics (NASDAQ:PLRX) Shares Up 5.6% After Analyst Upgrade americanbankingnews.com - April 22 at 10:24 AM
	Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $28.42 americanbankingnews.com - April 20 at 12:00 PM
	BTIG Research Initiates Coverage on Pliant Therapeutics (NASDAQ:PLRX) americanbankingnews.com - April 20 at 10:52 AM
	Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Down to $30.64 americanbankingnews.com - April 19 at 12:02 PM
	Pliant Therapeutics, Inc. (NASDAQ:PLRX) CEO Bernard Coulie Sells 3,500 Shares americanbankingnews.com - April 15 at 10:34 PM
	Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume americanbankingnews.com - April 15 at 11:40 AM
	Analyzing The Price Action In Pliant Therapeutics Stock Today msn.com - April 5 at 12:00 PM
	Pliant Therapeutics to Participate in Annual Needham Virtual Healthcare Conference finance.yahoo.com - April 5 at 12:00 PM
	We're Not Very Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate finance.yahoo.com - March 22 at 2:32 PM
	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 ... apnews.com - March 16 at 7:33 PM
	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - March 16 at 7:33 PM
	Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner finance.yahoo.com - March 16 at 9:30 AM
	Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner finance.yahoo.com - March 16 at 9:30 AM
	Pliant Therapeutics to Participate in Upcoming Virtual Investor Events finance.yahoo.com - February 18 at 1:01 PM
	Creating More Affordable Homes for Families in Red Lake finance.yahoo.com - February 17 at 9:45 AM
	Why a small Peninsula biotech thinks it can make a quick difference against Covid bizjournals.com - January 14 at 5:58 PM

Date	Company	Brokerage	Action
4/7/2021	Constellation Pharmaceuticals	Royal Bank of Canada	Reiterated Rating
1/25/2021	Constellation Pharmaceuticals	BMO Capital Markets	Upgrade
9/24/2020	Constellation Pharmaceuticals	Oppenheimer	Reiterated Rating
9/3/2020	Constellation Pharmaceuticals	Brookline Capital Management	Initiated Coverage
8/9/2020	Constellation Pharmaceuticals	Jefferies Financial Group	Reiterated Rating
8/6/2020	Constellation Pharmaceuticals	HC Wainwright	Reiterated Rating
6/24/2020	Constellation Pharmaceuticals	JMP Securities	Initiated Coverage
3/11/2020	Constellation Pharmaceuticals	Robert W. Baird	Lower Price Target
3/11/2020	Constellation Pharmaceuticals	Cowen	Reiterated Rating
2/13/2020	Constellation Pharmaceuticals	SunTrust Banks	Initiated Coverage
11/24/2020	Kiniksa Pharmaceuticals	Evercore ISI	Initiated Coverage
6/30/2020	Kiniksa Pharmaceuticals	The Goldman Sachs Group	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Bank of America	Boost Price Target
6/29/2020	Kiniksa Pharmaceuticals	Wedbush	Boost Price Target
3/11/2020	Kiniksa Pharmaceuticals	JPMorgan Chase & Co.	Boost Price Target
3/11/2019	Kiniksa Pharmaceuticals	Barclays	Initiated Coverage
2/1/2021	Omeros	UBS Group	Initiated Coverage
12/4/2020	Omeros	Maxim Group	Boost Price Target
5/12/2020	Omeros	Needham & Company LLC	Reiterated Rating
12/2/2020	Zogenix	Mizuho	Reiterated Rating
8/24/2020	Zogenix	Raymond James	Initiated Coverage
8/6/2020	Zogenix	Northland Securities	Reiterated Rating
6/26/2020	Zogenix	William Blair	Reiterated Rating
5/5/2020	Zogenix	Piper Sandler	Lower Price Target
3/5/2020	Zogenix	Citigroup	Initiated Coverage
2/28/2020	Zogenix	LADENBURG THALM/SH SH	Reiterated Rating
2/14/2020	Zogenix	Stifel Nicolaus	Reiterated Rating
1/21/2020	Zogenix	Guggenheim	Reiterated Rating
12/6/2019	Zogenix	Piper Jaffray Companies	Reiterated Rating
4/26/2021	Pliant Therapeutics	BTIG Research	Initiated Coverage
4/5/2021	Pliant Therapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources